Eptazocine hydrobromide

FABP-IN-1 (Compounds 4b) is a high affinity fatty acid binding protein (FABP) inhibitor. FABP-IN-1 inhibits FABP3 , FABP5 , and FABP7 with K i values of 0.69 μM, 0.55 μM and 0.67 μM, respectively. FABP-IN-1 displays potent antinociceptive effectsIn

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA) , with an IC 50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and

Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA) , with an IC 50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and